Departement of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, Messina, Italy.
Department of Chemical Sciences, University of Catania, Viale A. Doria 6, 95125, Catania, Italy.
Biomed Pharmacother. 2020 May;125:110023. doi: 10.1016/j.biopha.2020.110023. Epub 2020 Feb 25.
Several studies demonstrated the pharmacological actions of carnosine as well as hyaluronic acid (HA) during joint inflammation. In that regard, the aim of this study was to investigate the protective effect of a new HA -Carnosine conjugate (FidHycarn) on the modulation of the inflammatory response in mice subjected to collagen-induced arthritis (CIA). CIA was induced by two intradermal injections of 100 μl of an emulsion of collagen (CII) and complete Freund's adjuvant (CFA) at the base of the tail on day 0 and 21. At 35 day post CIA induction, the animals were sacrificed. CII injection caused erythema and edema in the hind paws, histological alterations with erosion of the joint cartilage as well as behavioral changes. Oral treatment with FidHycarn starting at the onset of arthritis (day 25) ameliorated the clinical signs, improved behavioral deficits as well as decreased histological and radiographic alterations. The degree of oxidative damage evaluated by inducible nitric oxide synthase (iNOS), nitrotyrosine, poly-ADP-ribose (PAR) expressions and malondialdehyde (MDA) levels, was also significantly reduced in Carnosine+HA association and FidHycarn treated mice. Moreover, the levels of proinflammatory cytokines and chemokines and cyclo-oxygenase COX-2 enzyme were also more significantly reduced by Carnosine+HA and FidHycarn compared to carnosine alone. However, interestingly, in some cases, the effects of FidHycarn were more important than Carnosine+HA association and not statistically different to methotrexate (MTX) used as positive control. Thus, the conjugation of Carnosine with HA (FidHycarn) could represent an interesting therapeutic strategy to combat arthritis disorders.
几项研究表明,肌肽和透明质酸(HA)在关节炎症中具有药理学作用。在这方面,本研究的目的是研究一种新的 HA-肌肽缀合物(FidHycarn)对胶原诱导性关节炎(CIA)小鼠炎症反应调节的保护作用。CIA 通过在尾根部皮内注射 100μl 胶原(CII)和完全弗氏佐剂(CFA)乳液在第 0 天和 21 天诱导。在 CIA 诱导后 35 天,处死动物。CII 注射导致后爪出现红斑和水肿、关节软骨侵蚀的组织学改变以及行为变化。从关节炎发作(第 25 天)开始口服 FidHycarn 治疗可改善临床症状、改善行为缺陷并减少组织学和放射学改变。诱导型一氧化氮合酶(iNOS)、硝基酪氨酸、聚二磷酸腺苷核糖(PAR)表达和丙二醛(MDA)水平评估的氧化损伤程度在肌肽+HA 联合和 FidHycarn 治疗的小鼠中也显著降低。此外,与单独肌肽相比,FidHycarn 还显著降低了促炎细胞因子和趋化因子以及环氧化酶 COX-2 酶的水平。然而,有趣的是,在某些情况下,FidHycarn 的作用比 Carnosine+HA 联合更为重要,且与作为阳性对照的甲氨蝶呤(MTX)无统计学差异。因此,肌肽与 HA 的缀合(FidHycarn)可能代表一种对抗关节炎疾病的有趣治疗策略。